Skip to main content

Table 2 Clinical evidence for adoptive transfer of EBV-specific T cells

From: Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation

Reference

Method

No. of patients

Results

Dose

In vitro stimulation and expansion

Rooney et al. (1995) [25]

Allogeneic EBV-specific CD8+ T cells

10

Therapy: 3/3 responders Prophylaxis: 7/7 virus free

0.2–1.2 × 108 cells/m2

Rooney et al. (1998) [26]

Allogeneic EBV-specific CD8+ T cells

39

Prophylaxis: all PTLD free

0.2–1.0 × 108 cells/m2

Haque et al. (2002) [50]

Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase I/II

8

4/8 remission

106 cells/kg

Haque et al. (2007) [51]

Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase II

33

14/33 complete remission 3/33 partial response

2 × 106 cells/kg

Heslop et al. (2010) [49]

Allogeneic EBV-specific CD8+ T cells

114

Therapy: 11/13 complete response prophylaxis: all PTLD free

1–5 × 107 cells/m2

Doubrovina et al. (2012) [63]

Allogeneic EBV-specific CD8+ T cells

19

13/19 complete response

106 cells/kg

Gallot et al. (2014) [64]

Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase I/II

11

4/10 responders

5 × 106 cells/kg

Withers et al. (2017 and 2018) [55, 59]

EBV-specific third-party CD8+ and CD4+ T cells phase I

1

0/1 responded

1 infusion of 1.37–5.0 × 107 cells/m2

Direct isolation via peptide-HLA multimers

Uhlin et al. (2010) [65]

Allogeneic EBV-specific CD8+ T cells using MHC-I-pentamers

1

1/1 complete response

1.1 × 104 cells/kg and 2 × 104 cells/kg

Direct isolation via cytokine-capture technique

Moosmann et al. (2010) [66]

EBV-specific polyclonal CD8+ and CD4+ T cells

6

3/6 responders

0.4–9.7 × 104 cells/kg

Icheva et al. (2013) [29]

EBV-specific polyclonal CD8+ and CD4+ T cells

10

7/10 responders

0.15–53.8 × 103 cells/kg

Kàllay et al. (2018) [43]

EBV-specific polyclonal CD8+ and CD4+ T cells

2

2/2 responders

1.8–2.3 × 104 cells/kg